Trojan, Lutz

[["dc.bibliographiccitation.firstpage","1706"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Cancer"],["dc.bibliographiccitation.lastpage","1712"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Zschäbitz, Stefanie"],["dc.contributor.author","Erlmeier, Franziska"],["dc.contributor.author","Stöhr, Christine"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Polifka, Iris"],["dc.contributor.author","Agaimy, Abbas"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Becker, Frank"],["dc.contributor.author","Wülfing, Christian"],["dc.contributor.author","Steffens, Sandra"],["dc.date.accessioned","2022-05-02T08:09:39Z"],["dc.date.available","2022-05-02T08:09:39Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.7150/jca.63509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107432"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.issn","1837-9664"],["dc.title","Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","481"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","GENDER MEDICINE"],["dc.bibliographiccitation.lastpage","489"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Otto, Wolfgang"],["dc.contributor.author","May, Matthias"],["dc.contributor.author","Fritsche, Hans-Martin"],["dc.contributor.author","Dragun, Duska"],["dc.contributor.author","Aziz, Atiqullah"],["dc.contributor.author","Gierth, Michael"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Moritz, Rudolf"],["dc.contributor.author","Ellinger, Joerg"],["dc.contributor.author","Tilki, Derya"],["dc.contributor.author","Buchner, Alexander"],["dc.contributor.author","Hoefner, Thomas"],["dc.contributor.author","Brookman-May, Sabine"],["dc.contributor.author","Nuhn, Philipp"],["dc.contributor.author","Gilfrich, Christian"],["dc.contributor.author","Roigas, Jan"],["dc.contributor.author","Zacharias, Mario"],["dc.contributor.author","Denzinger, Stefan"],["dc.contributor.author","Hohenfellner, Markus"],["dc.contributor.author","Haferkamp, Axel"],["dc.contributor.author","Mueller, Stefan C."],["dc.contributor.author","Kocot, Arkadius"],["dc.contributor.author","Riedmiller, Hubertus"],["dc.contributor.author","Wieland, Wolf F."],["dc.contributor.author","Stief, Christian G."],["dc.contributor.author","Bastian, Patrick J."],["dc.contributor.author","Burger, Maximilian"],["dc.date.accessioned","2018-11-07T09:02:34Z"],["dc.date.available","2018-11-07T09:02:34Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: Outcome of patients with urothelial carcinoma of the bladder (UCB) varies between sexes. Although overall incidence is higher in men, cancer-specific survival (CSS) has been suggested to be lower in women. Although the former effect is attributed to greater exposure to carcinogens in men, the latter has not been elucidated. Objectives: The aim of the study was to identify sex-specific outcomes based on one of the largest databases of patients with UCB who underwent radical cystectomy (RC). Methods: This retrospective multicenter series comprised 2483 patients in Stage M0 who underwent RC for UCB from 1989 to 2008; 20.4% of patients were women. The impact of sex on CSS in the entire study group and in specific subgroups was analyzed. The median follow-up time was 42 months (interquartile range, 21-79). Results: Histopathologic criteria of pathologic tumor (pT), pathologic nodal (pN), grade, lymphovascular invasion (LVI), and associated carcinoma in situ (CIS) of the study did not differ between sexes. The percentage of female patients increased over time. Five-year CSS in female patients was significantly lower than in male patients (60% vs 66%; P = 0.005). In multivariate analysis adjusted to other covariates, tumor stage >= pT3 (hazard ratio [HR] = 2.44; P < 0.001), positive pN status (HR = 1.91; P < 0.001), LVI (HR = 1.48; P < 0.001), lower count of lymph nodes removed (HR = 0.98; P = 0.002), older age (HR = 1.01; P < 0.001), female gender (HR = 1.26; P = 0.011) had an independent impact on CSS. Deterioration of CSS in female patients was pronounced when LVI was present (HR = 1.57; P < 0.001) and when RC was performed in the earlier time period (HR = 2.44; P < 0.001). However, women showed significantly lower perioperative mortality (within 90 days after RC) compared with men. Conclusions: After RC for UCB, cancer-specific mortality was higher in female patients; this disadvantage was more pronounced in earlier time periods. In addition, worse outcome of women with verified LVI was shown to be comparable with men. These findings were suggestive of different tumor biology and potentially unequal access to timely RC in earlier time periods because of reduced awareness of UCB in women. Further studies are required to improve UCB outcome in both sexes, notably in female patients. (Gend Med. 2012;9:481-489) (c) 2012 Elsevier HS Journals, Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.genm.2012.11.001"],["dc.identifier.isi","000312676000012"],["dc.identifier.pmid","23217567"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24716"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Excerpta Medica Inc-elsevier Science Inc"],["dc.relation.issn","1550-8579"],["dc.title","Analysis of Sex Differences in Cancer-Specific Survival and Perioperative Mortality Following Radical Cystectomy: Results of a Large German Multicenter Study of Nearly 2500 Patients with Urothelial Carcinoma of the Bladder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Discover Oncology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Zschäbitz, Stefanie"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Stöhr, Christine"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Polifka, Iris"],["dc.contributor.author","Agaimy, Abbas"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Becker, Frank"],["dc.contributor.author","Wülfing, Christian"],["dc.contributor.author","Steffens, Sandra"],["dc.date.accessioned","2022-10-04T10:21:18Z"],["dc.date.available","2022-10-04T10:21:18Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. Enfortumab vedotin-ejf (EV) is an antibody drug conjugate that targets Nectin-4. The aim of our study was to investigate the expression of Nectin-4 in a large cohort of papillary RCC specimens.\r\n \r\n \r\n Patients and methods\r\n Specimens were derived from the PANZAR consortium (Erlangen, Heidelberg, Herne, Homburg, Mainz, Mannheim, Marburg, Muenster, LMU Munich, TU Munich, and Regensburg). Clinical data and tissue samples from n = 190 and n = 107 patients with type 1 and 2 pRCC, respectively, were available. Expression of Nectin-4 was determined by immunohistochemistry (IHC).\r\n \r\n \r\n Results\r\n In total, Nectin-4 staining was moderately or strongly positive in of 92 (48.4%) of type 1 and 39 (36.4%) type 2 of pRCC cases. No associations between Nectin-4 expression and age at diagnosis, gender, grading, and TNM stage was found. 5 year overall survival rate was not statistically different in patients with Nectin-4 negative versus Nectin-4 positive tumors for the overall cohort and the pRCC type 2 subgroup, but higher in patient with Nectin-4 positive pRCC type 1 tumors compared to Nectin-4 negative tumors (81.3% vs. 67.8%, p = 0.042).\r\n \r\n \r\n Conclusion\r\n Nectin-4 could not be confirmed as a prognostic marker in pRCC in general. Due to its high abundance on pRCC specimens Nectin-4 is an interesting target for therapeutical approaches e.g. with EV. Clinical trials are warranted to elucidate its role in the pRCC treatment landscape."],["dc.description.sponsorship"," Deutsche Forschungsgemeinschaft http://dx.doi.org/10.13039/501100001659"],["dc.description.sponsorship"," Deutsche Gesellschaft für Urologie http://dx.doi.org/10.13039/501100006186"],["dc.description.sponsorship","Medizinische Hochschule Hannover (MHH)"],["dc.identifier.doi","10.1007/s12672-022-00558-2"],["dc.identifier.pii","558"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114372"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-600"],["dc.relation.eissn","2730-6011"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.relation.orgunit","Klinik für Urologie"],["dc.relation.orgunit","Institut für Pathologie"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Expression of nectin-4 in papillary renal cell carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Urologia Internationalis"],["dc.bibliographiccitation.lastpage","9"],["dc.contributor.author","Mondorf, Yvonne"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Ivanyi, Philipp"],["dc.contributor.author","Stöhr, Christine"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Polifka, Iris"],["dc.contributor.author","Agaimy, Abbas"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Becker, Frank"],["dc.contributor.author","Erlmeier, Franziska"],["dc.date.accessioned","2022-07-01T07:35:19Z"],["dc.date.available","2022-07-01T07:35:19Z"],["dc.date.issued","2022"],["dc.description.abstract","Introduction: Programmed death-1 ligand (PD-L1) has been often studied in different types of renal-cell carcinoma (RCC). For example, in clear-cell renal carcinoma it is well established that programmed death-1 receptor and PD-L1 are important prognostic markers. In contrast, the role of programmed death-2 ligand (PD-L2) as prognostic marker remains unclear. The aim of this study was to evaluate if PD-L2 expression could play a role as a prognostic marker for papillary RCC (pRCC). Methods: The patients’ sample collection was a joint collaboration of the PANZAR consortium. Patients’ medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of PD-L2 was determined by immunohistochemistry. In total, PD-L2 staining was evaluable in 185 of 240 type 1 and 99 of 128 type 2 pRCC cases. Results: PD-L2 staining was positive in 67 (36.2%) of type 1 and in 31 (31.3%) of type 2 pRCC specimens. The prevalence of PD-L2+ cells was significantly higher in high-grade type 1 tumors (p = 0.019) and in type 2 patients with metastasis (p = 0.002). Kaplan-Meier analysis disclosed significant differences in 5-year overall survival (OS) for patients with PD-L2− compared to PD-L2+ in pRCC type 1 of 88.4% compared to 73.6% (p = 0.039) and type 2 of 78.8% compared to 39.1% % (p < 0.001). However, multivariate analysis did not identify the presence of PD-L2+ cells neither in type 1 nor type 2 pRCC as an independent predictor of poor OS. Discussion/Conclusion: PD-L2 expression did not qualify as an independent prognostic marker in pRCC. Future studies will have to determine whether anti-PD-L2-targeted treatment may play a role in pRCC and expression can potentially serve as a predictive marker for these therapeutic approaches."],["dc.identifier.doi","10.1159/000525016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112138"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-581"],["dc.relation.eissn","1423-0399"],["dc.relation.issn","0042-1138"],["dc.title","The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","S0344033822000450"],["dc.bibliographiccitation.firstpage","153802"],["dc.bibliographiccitation.journal","Pathology - Research and Practice"],["dc.bibliographiccitation.volume","231"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Zschäbitz, Stefanie"],["dc.contributor.author","Stöhr, Christine"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Polifka, Iris"],["dc.contributor.author","Agaimy, Abbas"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Becker, Frank"],["dc.contributor.author","Wülfing, Christian"],["dc.contributor.author","Erlmeier, Franziska"],["dc.date.accessioned","2022-04-01T10:02:31Z"],["dc.date.available","2022-04-01T10:02:31Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1016/j.prp.2022.153802"],["dc.identifier.pii","S0344033822000450"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105934"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.issn","0344-0338"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","The prognostic impact of Claudin 6 in papillary renal cell carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","212"],["dc.bibliographiccitation.journal","Human Pathology"],["dc.bibliographiccitation.lastpage","223"],["dc.bibliographiccitation.volume","83"],["dc.contributor.author","Polifka, Iris"],["dc.contributor.author","Agaimy, Abbas"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Spath, Verena"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Stöckle, Michael"],["dc.contributor.author","Becker, Frank"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Wülfing, Christian"],["dc.contributor.author","Schrader, Andres J."],["dc.contributor.author","Barth, Peter"],["dc.contributor.author","Staehler, Michael"],["dc.contributor.author","Stief, Christian"],["dc.contributor.author","Hohenfellner, Markus"],["dc.contributor.author","Macher-Göppinger, Stephan"],["dc.contributor.author","Wullich, Bernd"],["dc.contributor.author","Noldus, Joachim"],["dc.contributor.author","Brenner, Walburgis"],["dc.contributor.author","Roos, Frederik C."],["dc.contributor.author","Walter, Bernhard"],["dc.contributor.author","Otto, Wolfgang"],["dc.contributor.author","Burger, Maximilian"],["dc.contributor.author","Höfler, Heinz"],["dc.contributor.author","Haferkamp, Axel"],["dc.contributor.author","Geppert, Carol I."],["dc.contributor.author","Stöhr, Christine"],["dc.contributor.author","Hartmann, Arndt"],["dc.date.accessioned","2020-12-10T14:24:26Z"],["dc.date.available","2020-12-10T14:24:26Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.humpath.2018.08.006"],["dc.identifier.issn","0046-8177"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72249"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","57"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Urologia Internationalis"],["dc.bibliographiccitation.lastpage","64"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Martini, Thomas"],["dc.contributor.author","Aziz, Atiqullah"],["dc.contributor.author","Roghmann, Florian"],["dc.contributor.author","Rink, Michael"],["dc.contributor.author","Chun, Felix K-H."],["dc.contributor.author","Fisch, Margit"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Hakenberg, Oliver W."],["dc.contributor.author","Zastrow, Stefan"],["dc.contributor.author","Wirth, Manfred P."],["dc.contributor.author","Moersdorf, Johannes"],["dc.contributor.author","Brookman-May, Sabine"],["dc.contributor.author","Stief, Christian G."],["dc.contributor.author","Haferkamp, Axel"],["dc.contributor.author","Wagenlehner, Florian"],["dc.contributor.author","Hohenfellner, Markus"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Lusuardi, Lukas"],["dc.contributor.author","Grimm, Marc-Oliver"],["dc.contributor.author","Mueller, Stephan C."],["dc.contributor.author","Roigas, Jan"],["dc.contributor.author","Bastian, Patrick J."],["dc.contributor.author","Gierth, Michael"],["dc.contributor.author","Burger, Maximilian"],["dc.contributor.author","Pychar, Armin"],["dc.contributor.author","Seitz, Christian"],["dc.contributor.author","May, Matthias"],["dc.contributor.author","Bolenz, Christian"],["dc.date.accessioned","2018-11-07T10:21:09Z"],["dc.date.available","2018-11-07T10:21:09Z"],["dc.date.issued","2016"],["dc.description.abstract","Introduction: We aimed at developing and validating a pre-cystectomy nomogram for the prediction of locally advanced urothelial carcinoma of the bladder (UCB) using clinicopathological parameters. Materials and Methods: Multicenter data from 337 patients who underwent radical cystectomy (RC) for UCB were prospectively collected and eligible for final analysis. Univariate and multivariate logistic regression models were applied to identify significant predictors of locally advanced tumor stage (pT3/4 and/or pN+) at RC. Internal validation was performed by bootstrapping. The decision curve analysis (DCA) was done to evaluate the clinical value. Results: The distribution of tumor stages pT3/4, pN+ and pT3/4 and/or pN+ at RC was 44.2, 27.6 and 50.4%, respectively. Age (odds ratio (OR) 0.980; p < 0.001), advanced clinical tumor stage (cT3 vs. cTa, cTis, cT1; OR 3.367; p < 0.001), presence of hydronephrosis (OR 1.844; p = 0.043) and advanced tumor stage T3 and/or N+ at CT imaging (OR 4.378; p < 0.001) were independent predictors for pT3/4 and/or pN+ tumor stage. The predictive accuracy of our nomogram for pT3/4 and/or pN+ at RC was 77.5%. DCA for predicting pT3/4 and/or pN+ at RC showed a clinical net benefit across all probability thresholds. Conclusion: We developed a nomogram for the prediction of locally advanced tumor stage pT3/4 and/or pN+ before RC using established clinicopathological parameters. (C) 2015 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000433606"],["dc.identifier.isi","000368974200010"],["dc.identifier.pmid","26139354"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42036"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1423-0399"],["dc.relation.issn","0042-1138"],["dc.title","Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy - A Prospective Multicenter Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Human Pathology"],["dc.bibliographiccitation.lastpage","10"],["dc.bibliographiccitation.volume","121"],["dc.contributor.author","Erlmeier, Franziska"],["dc.contributor.author","Bruecher, Benedict"],["dc.contributor.author","Stöhr, Christine"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Polifka, Iris"],["dc.contributor.author","Agaimy, Abbas"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Becker, Frank"],["dc.contributor.author","Wülfing, Christian"],["dc.contributor.author","Steffens, Sandra"],["dc.date.accessioned","2022-04-01T10:02:26Z"],["dc.date.available","2022-04-01T10:02:26Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1016/j.humpath.2021.12.007"],["dc.identifier.pii","S004681772100215X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105911"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.issn","0046-8177"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","cMET: a prognostic marker in papillary renal cell carcinoma?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]